Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICHE trial in early-stage colon cancer
NL-OMON58997Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relatlimab and nivolumab in colon adenocarcinoma and Rectosigmoid Adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Major pathologic response rate. Started Jan 2017; status: recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
colon adenocarcinomaRectosigmoid Adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58997.